| Bioactivity | FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29)[1]. FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC50 of 18.6 nM[2]. |
| Target | IC50: 10 nM (FASN)EC50: 18.6 nM (SARS-CoV-2) |
| Invitro | The FASN inhibitor, FASN-IN-4 tosylate inhibits SARS-CoV-2 replication, and has the potential for COVID-19 research[2]. |
| Name | FASN-IN-4 tosylate |
| Formula | C33H35N3O7S2 |
| Molar Mass | 649.78 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Nicholas D. Adams, et al. Fatty acid synthase inhibitors. WO2012064642A1. [2]. Junjun Chu, et al. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. Nat Metab. 2021 Nov;3(11):1466-1475. |